Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.57 |
| ▸ | METAP1 | P53582 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022054 | 0.90 | METAP2 (0.56) | METAP2METAP1NPC1RAB9AHIF1A | |
| SCHEMBL21880739 | 0.90 | METAP2 (0.56) | METAP2METAP1NPC1RAB9AHIF1A | |
| SCHEMBL15200377 | 0.89 | METAP2 (0.48) | METAP2METAP1CTSS | |
| SCHEMBL15200384 | 0.89 | METAP2 (0.51) | METAP2METAP1CTSS | |
| SCHEMBL14984990 | 0.88 | METAP2 (0.75) | METAP2METAP1CTSS | |
| SCHEMBL14984956 | 0.88 | HPGD (0.49) | METAP2METAP1NPC1RAB9AMTNR1A | |
| SCHEMBL7350315 | 0.85 | METAP2 (0.77) | METAP2METAP1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7362199 | 0.84 | METAP2 (0.76) | METAP2METAP1NPC1RAB9A | |
| SCHEMBL19123614 | 0.83 | METAP2 (0.54) | METAP2METAP1NPC1RAB9ACTSS | |
| SCHEMBL25858182 | 0.83 | METAP2 (0.49) | METAP2METAP1NPC1RAB9ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-3858385-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3574922-A1 | MODIFIED OR POLYMER-CONJUGATED FUMAGILLOL METAP2 INHIBITORS FOR USE IN IMPROVING OR RESTORING INSULIN SENSITIVITY | Syndevrx, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-10010544-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9730955-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160346244-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160256483-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9433600-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9173956-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | SYNDEVRX, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | SynDecRx, Inc. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 831/4885 |
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | METAP2, MTX2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 831/4885 |
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 831/4885 |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885METAP1 1935/4885NPC1 235/4885 |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 831/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885METAP1 1935/4885NPC1 235/4885 |
| US-20160256483-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 831/4885 |
| US-20160346244-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
| US-10010544-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | METAP2 1/4885METAP1 3/4885NPC1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.